[Anthracycline use in breast cancer based on our current knowledge].

Authors

Gábor Rubovszky, Alíz Nikolényi, Katalin Boér

Published in

Magyar onkologia. Volume 70. Issue 3. Pages 289-294. Sep 11, 2026. Epub Mar 22, 2026.

Abstract

Anthracyclines have been a standard component of the curative treatment of breast cancer for decades. Due to the emergence of new anticancer drugs (taxanes, immunotherapy, antibody-drug conjugates) and potentially life-threatening and long-term side effects of anthracyclines, the range of indications for their use has narrowed in recent years and seems to be becoming clearer. The classification of breast cancers according to molecular subgroups and the ever-expanding clinical data allow the choice of applied treatments to be increasingly individualized, which has led to the decline of anthracyclines in most breast cancer subtypes. Our goal with our summary work is to facilitate everyday decisions regarding the use of anthracyclines by summarizing the available clinical evidence.

PMID:
42731007
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.